Climb Bio (NASDAQ:CLYM) Trading Down 6.1% – Here’s What Happened

Shares of Climb Bio, Inc. (NASDAQ:CLYM) were down 6.1% during mid-day trading on Thursday . The stock traded as low as $15.35 and last traded at $15.10. Approximately 666,332 shares changed hands during mid-day trading, a decline of 29% from the average session volume of 943,474 shares. The stock had previously closed at $16.08.

Climb Bio News Roundup

Here are the key news stories impacting Climb Bio this week:

• Positive Sentiment: Climb Bio’s Phase 2 trial in China is advancing, providing continued progress for the company’s clinical pipeline. However, investors are also assessing whether that progress is already reflected in the valuation. Climb Bio (CLYM) Advances Phase 2 Trial In China, Is The Valuation Already Priced In?
• Positive Sentiment: HC Wainwright raised its Climb Bio loss estimates across several periods, implying better-than-previously-expected results: FY2026 EPS to $(0.76) from $(0.93), Q3 2026 to $(0.20) from $(0.23), Q4 2026 to $(0.19) from $(0.22), and FY2027 to $(0.98) from $(0.99). The firm reiterated its Buy rating and $24 price target, well above the recent trading level.
• Neutral Sentiment: Short interest was reported at zero shares as of August 25, unchanged from August 10. This indicates no measurable short-selling pressure, although the data provides little additional directional information.
• Neutral Sentiment: Unusually heavy call-option activity occurred Wednesday, with 3,024 calls traded versus typical volume of 360. The activity may reflect bullish speculation, but options volume alone does not confirm that traders expect a sustained advance.
• Negative Sentiment: Put-option activity surged Thursday to 7,091 contracts, approximately 1,046% above the average daily volume of 619. The sharp increase points to heightened hedging or bearish speculation and is the clearest near-term negative market signal.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on CLYM shares. Wedbush reaffirmed an “outperform” rating and issued a $20.00 price target on shares of Climb Bio in a research report on Wednesday, August 19th. Guggenheim initiated coverage on Climb Bio in a report on Monday, June 8th. They set a “buy” rating and a $35.00 price objective on the stock. Wall Street Zen raised shares of Climb Bio from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. Royal Bank Of Canada began coverage on Climb Bio in a research note on Monday, August 3rd. They set an “outperform” rating and a $23.00 price objective for the company. Finally, Robert W. Baird set a $21.00 target price on shares of Climb Bio in a research note on Wednesday, May 6th. Two analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $23.08.

Climb Bio Stock Performance

The firm has a market capitalization of $867.28 million, a PE ratio of -18.22 and a beta of 0.08. The company’s fifty day moving average price is $13.69 and its two-hundred day moving average price is $10.37.

Climb Bio (NASDAQ:CLYM) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.03. On average, equities analysts expect that Climb Bio, Inc. will post -0.82 earnings per share for the current year.

Institutional Investors Weigh In On Climb Bio

Institutional investors have recently bought and sold shares of the business. MPM Bioimpact LLC purchased a new stake in Climb Bio during the 4th quarter worth $10,686,000. BlackRock Inc. purchased a new position in Climb Bio in the second quarter valued at about $30,708,000. Braidwell LP lifted its stake in shares of Climb Bio by 102.6% during the second quarter. Braidwell LP now owns 3,099,027 shares of the company’s stock worth $40,411,000 after purchasing an additional 1,569,352 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its stake in shares of Climb Bio by 265.1% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,923,639 shares of the company’s stock worth $7,695,000 after purchasing an additional 1,396,722 shares in the last quarter. Finally, ADAR1 Capital Management LLC boosted its position in shares of Climb Bio by 972.8% in the fourth quarter. ADAR1 Capital Management LLC now owns 1,432,475 shares of the company’s stock worth $5,730,000 after buying an additional 1,298,945 shares during the period. 69.76% of the stock is currently owned by hedge funds and other institutional investors.

Climb Bio Company Profile

Climb Bio Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered protein therapeutics for the treatment of cancer and immune-mediated disorders. The company’s mission centers on designing biologics with enhanced specificity and functional activity to engage key cellular targets and improve patient outcomes in areas of high unmet need.

At the heart of Climb Bio’s approach is its proprietary protein engineering platform, which combines mammalian cell display, directed evolution and computational modeling.